Blog Archives

Warning: Use of undefined constant php - assumed 'php' (this will throw an Error in a future version of PHP) in /nas/content/live/enzyvant4524/wp-content/themes/enzyvant-v2/archive.php on line 66

Blog Archives

Uncategorized

SCOPE Europe 2022

Altavant Sciences Highlights Ongoing Phase 2b ELEVATE 2 Study of Rodatristat Ethyl in Patients with Pulmonary Arterial Hypertension at European Respiratory Society Annual Congress

Altavant Sciences Reports Rodatristat Ethyl PK/PD Analysis at ATS Supporting Doses Selected for Phase 2b ELEVATE 2 Study

Altavant Sciences Provides Update on Clinical Plan for PAH Candidate, Rodatristat Ethyl, at Upcoming American Thoracic Society Annual Meeting

Altavant Sciences Advances Rodatristat Ethyl into Phase 2b Clinical Trial for Pulmonary Arterial Hypertension

Altavant Sciences Finds Nebulized ALTA-2530 Retains Potency and Reaches Target Lung Tissues, Supporting Continued Investigation for Treatment of BOS

Altavant Sciences Initiates Chemical Lung Injury Program in Collaboration with the BARDA and NIAID

Altavant Sciences Presentation at ATS 2020 Confirms Minimal Brain Exposure of Peripherally Acting Serotonin Modulator, Rodatristat Ethyl, in Clinical Development for PAH

Altavant Sciences Appoints Respiratory Disease Medical Expert as Chief Medical Officer

Altavant Sciences Acquires Onspira Therapeutics, Adding a Potentially Life-Saving Treatment for Post-Lung Transplant Patients to the Altavant Pipeline

Altavant Sciences Presents Data at CHEST 2019 Supporting Once-Daily Dosing of Rodatristat Ethyl for the Treatment of Pulmonary Arterial Hypertension

Altavant Sciences to Present Data Supporting Once-Daily Dosing of Rodatristat Ethyl at CHEST 2019

Altavant Sciences Presents Data at ERS International Congress 2019 Demonstrating Strong Safety and Tolerability Profile of Rodatristat Ethyl

Altavant Sciences to Present New Rodatristat Ethyl Clinical Biomarker and Safety Findings at the ERS International Congress 2019

Sumitomo Dainippon Pharma and Roivant Sciences Enter into a Memorandum of Understanding to Create Broad Strategic Alliance to Deliver Promising New Medicines to Patients

Altavant Sciences Presents Patient-Centric Approach to Drug Development at PHA’s Annual PHPN Symposium

Altavant Sciences Initiates Phase 2a Study of Rodatristat Ethyl in Pulmonary Arterial Hypertension

Altavant Sciences to Provide Clinical Update at 2019 Respiratory Innovation Summit

Altavant Sciences to Present Data Supporting Planned Phase 2 Clinical Program for Rodatristat Ethyl in Patients with Pulmonary Arterial Hypertension at PVRI World Congress

Altavant Sciences Appoints Lyn Baranowski Chief Operating Officer

Enzyvant Receives FDA Rare Pediatric Disease Designation for Investigational Therapy RVT-802

Enzyvant Receives FDA Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy Designation for Investigational Therapy RVT-802

Rare Disease Day

RARE in the Square

Enzyvant to Develop Novel Biologic Therapy for Complete DiGeorge Syndrome

Roivant Sciences and Plexcera Therapeutics Announce the Formation of Enzyvant Sciences to Focus on the Treatment of Farber Disease

Press Releases

Enzyvant Announces Merger with Altavant

Altavant Sciences Presents Data Showing Potential for Combination of Rodatristat Ethyl and Ambrisentan in Model of Pulmonary Arterial Hypertension

Altavant Sciences Presented Data at ISHLT Showing Potency and Distribution of Bronchiolitis Obliterans Candidate, ALTA-2530

Altavant Sciences to Present Data at ISHLT Showing Potency and Distribution of Bronchiolitis Obliterans Candidate, ALTA-2530

Enzyvant Announces Plans to Expand Regenerative Medicine Manufacturing Capabilities

Sumitovant and Enzyvant Appoint Bill Symonds, CEO of Altavant Sciences, as Interim Chief Executive Officer of Enzyvant

Enzyvant Appoints Johanna Rossell as Chief Commercial Officer

Enzyvant Receives FDA Approval for RETHYMIC® (allogeneic processed thymus tissue-agdc), a One-Time Regenerative Tissue-Based Therapy for Pediatric Congenital Athymia

Enzyvant Announces Publication of Positive Clinical Data in Pediatric Patients with Congenital Athymia Treated with Investigational RVT-802 (allogeneic processed thymus tissue-agdc)

Enzyvant Announces First-Ever Data on Burden of Illness and Costs of Supportive Care for Pediatric Congenital Athymia

Aceragen Launches with Acquisition of Enzyvant‘s Investigational Therapy for Farber Disease and $35 Million Product Financing with NovaQuest

ENZYVANT Resubmits Biologics Licensing Application (BLA) to FDA for RVT-802 for Pediatric Congenital Athymia

Sumitomo Dainippon Pharma Completes the Formation of the Strategic Alliance with Roivant Sciences

Sumitomo Dainippon Pharma and Roivant Sciences Sign Definitive Agreement for Strategic Alliance

Enzyvant Appoints Jeb Ledell as Chief Operating Officer

Enzyvant Announces FDA Acceptance of Biologics License Application (BLA) and Priority Review Status for RVT-802, a Novel Investigational Tissue-Based Regenerative Therapy for Pediatric Congenital Athymia

Enzyvant’s Investigational Regenerative Treatment (RVT-802) for Congenital Athymia to be Discussed in Symposium, Platform Presentation and Poster Session at Clinical Immunology Society Meeting

Enzyvant Appoints Industry Veteran Rachelle Jacques as Chief Executive Officer

Enzyvant Announces Initiation of RVT-802 Rolling BLA Submission for the Treatment of Complete DiGeorge Anomaly

Events

43rd Annual Meeting & Scientific Sessions of the ISHLT

Alliance for Regenerative Medicine (ARM) Cell & Gene Meeting on the Mediterranean

ACC.23 Together With WCC

PCMA Business Forum 2023

American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting 2023

45th Annual Pulmonary and Allergy Update

American Thoracic Society (ATS) 2022

International Society for Heart & Lung Transplantation (ISHLT)

European Respiratory Society International Congress 2021

American Thoracic Society 2021

International Society for Heart & Lung Transplantation 2021

American Thoracic Society 2020

ERS 2019

67th Conference on Mass Spectrometry and Allied Topics

PVRI 2019

Contact us for more information

43rd Annual Meeting & Scientific Sessions of the ISHLT